Aloracetam

Aloracetam

Systematic (IUPAC) name
N-[2-(3-Formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide
Clinical data
Legal status
Legal status	US: Not FDA approved; Unscheduled
Identifiers
CAS Number	119610-26-3
ATC code	none
PubChem	CID 178134
ChemSpider	155069
UNII	U0RKZ75D0T
ChEMBL	CHEMBL2104637
Chemical data
Formula	C11H16N2O2
Molar mass	208.257 g/mol
SMILES CC1=CC(=C(N1CCNC(=O)C)C)C=O
InChI InChI=1S/C11H16N2O2/c1-8-6-11(7-14)9(2)13(8)5-4-12-10(3)15/h6-7H,4-5H2,1-3H3,(H,12,15) Key:ZUQSGZULKDDMEW-UHFFFAOYSA-N
(verify)

Aloracetam (INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds.^[1][2][3] It was studied by Aventis for the treatment of Alzheimer's disease,^[4] but was never marketed.

See also

• Piracetam

References

1. "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" (PDF). World Health Organization. 2011. Retrieved 22 May 2015.
2. Charles F. George (7 July 1998). Drug Therapy in Old Age. Wiley. ISBN 978-0-471-94149-1.
3. C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 615–. ISBN 978-0-412-46630-4.
4. Fischer F, Matthisson M, Herrling P. List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Diseases 2004;1:50–70.